

Supplemental Tables

Supplemental Table 1. Estimated Power (1- β) for Lipid Endpoints

Treatment Effect	Non HDL-C	Fasting Triglycerides	VLDL-C	HDL-C
Niacin	0.89	>0.99	0.99	0.98
P-OM3	0.44	0.82	0.66	0.46
Interaction	0.28	0.26	0.27	0.14

The pre and post treatment group means were taken from a 2x2 factorial *pilot* study (20) given with P-OM3 and Niacin. PROC GLMPOWER was used to determine the power for the main effects and the interaction effect using 15 subjects per group, with a two-sided critical level $\alpha = 0.05$. Since only aggregate data were available from Isley et al., the standard deviations (SD) for the differences in group means were calculated assuming a 0.7 correlation between pre and post measurements; and then the SD was pooled among the four groups. Two additional subjects per group were recruited to offset potential losses during follow up.


Supplemental Table 2. Flushing Outcome (Yes/No); N=58

Visit	Dual Placebo	ERN	P- OM3	Combination
Baseline	7/7	4/10	5/11	4/9
8 Weeks	4/10	12/2	5/11	10/3
16 Weeks	6/8	12/2	10/6	11/2
P-value*	0.45	0.01	1.00	0.03
P-value†	1.00	0.02	0.13	0.04

McNemar's exact test between baseline and 8 weeks* (16 weeks†).

Supplemental Figures

Supplemental Figure 1



Supplemental Figure 1: Omega-3 Index response to P-OM3 therapy (n=30). Each subject's Omega-3 Index, which is the red blood cell EPA and DHA content, at baseline and end of treatments (16 weeks) are shown in the P-OM3 treated subjects. The index of every subject receiving P-OM3 therapy increased, which is indicative of good compliance; $p < 0.0001$.